Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
🙌 It's Here: the Only Stock Screener You'll Ever Need Get Started
AbbVie's Botox, dermal fillers face slowdown jitters
Published Oct 28, 2022 07:47AM ET
Updated Oct 28, 2022 10:41AM ET
© Reuters. FILE PHOTO: A vial of Botox, owned by AbbVie, is seen next to its packaging in a photo illustration in Manhattan, New York, U.S., December 8, 2021. REUTERS/Andrew Kelly
By Manas Mishra
(Reuters) -Demand for AbbVie Inc (NYSE:ABBV)'s Botox anti-wrinkle injection and the popular facial filler Juvederm would be hit well into the next year by inflation and low consumer confidence, the company said on Friday.
Abbvie's shares were down 4.3% at $146.69 in morning trade, wiping over $12 billion in market capitalization.
The company, which also makes one of the world's bestselling drugs – Humira, is one of the rare few large drugmakers directly exposed to inflationary pressures.
AbbVie lowered its full-year sales forecast for its portfolio of "medical aesthetic" products used in cosmetic procedures by $600 million to $5.3 billion, but said it expects the impact to be "transient" after a near-term hit.
Chief Executive Officer Richard Gonzalez said the company's aesthetics business would face an impact for a significant part of 2023.
"As consumer confidence improves, we would once again expect the market growth to accelerate. Our aesthetics portfolio experienced a rapid and sustained recovery following the 2008, 2009 recession."
AbbVie gained the aesthetic products through its $63 billion deal for Allergan (NYSE:AGN), as it sought to sustain sales growth once rheumatoid Humira goes off-patent in the United States next year.
AbbVie said its contract negotiations with insurers and pharmacy benefit managers on Humira for the next year were proceeding well, but noted that the pricing of those rivals would determine the drug's sales next year.
Sales of Botox for cosmetic uses came in at $637 million during the third quarter, below estimates of $640.17 million, while sales of Juvederm were $352 million, also missing estimates of $360 million, according to Refinitiv data.
Also weighing on sales, AbbVie now expects 2022 sales of $2 billion from leukemia drug Venclexta, from $2.3 billion previously, due to soft demand.
Net revenue rose 3.3% to $14.81 billion, but fell short of estimates of $14.91 billion.
However, AbbVie earned $3.66 per share, excluding one-off items, beating estimates of $3.57 per share.
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.